Pearl Health, a provider of a data-driven clinical decision-making support platform for value-based care primary care providers, raised $75 million in Series B funding.
The latest funding round includes $55 million in equity investment and $20 million in debt financing.
Andreessen Horowitz’s Growth Fund and Viking Global Investors led the investment round with follow-on funding from returning investors, including AlleyCorp, SV Angel’s Growth Fund.
Including the latest funding round, Pearl has raised over $100 million in funding to date, according to the company’s press statement.
Commenting on the funding news announcement, Pearl Health Co-Founder and CEO Michael Kopko said: “This latest round of funding, combined with our previous investments, will allow us to expand our network and accelerate the development of innovative solutions that place providers at the center of healthcare delivery and cost management.”
Investors
Andreessen Horowitz (a16z) is a venture capital firm that backs entrepreneurs building the future through technology. a16z is stage agnostic, investing in seed to venture to late-stage technology companies across industries, including bio + healthcare, consumer, crypto, enterprise, fintech, and gaming. According to our database, a16z has invested more than $4 billion in digital health and healthcare technology companies to date. According to our investment tracker, the firm’s investment portfolio includes – Flexpa, Ultima Genomics, Turquoise Health, Levels, Valar Labs, Memora Health, Topography Health, Wonderschool, Ribbon Health, Patina Health, Marley Medical, Sprinter Health, Honor, Thyme Care, Pearl Health, Bayesian Health, Otter, Zus Health, Headway, Firefly Health, AKASA (fak Alpha Health), and Komodo Health.
“Pearl Health has done a great job of developing software to help providers achieve their goals around value-based care,” said Scott Kupor, Managing Partner at Andreessen Horowitz, who recently joined Pearl Health’s Board of Directors. “This new round of funding will help them significantly expand their market presence and bring their solution to a much wider audience.”
Clinical intelligence startups
According to our database, clinical intelligence and clinical decision software solutions providers have raised close to $15 billion in funding. More recently, Fountain Life, an AI-powered precision diagnostics solution for care providers to detect cancer, heart disease, and dementia in their earliest stages, received $15 million in funding from Eos Venture Partners and Newcross Healthcare. Ibex Medical Analytics, a provider of AI-guided cancer diagnostic solutions for pathologists, raised $10 million in debt funding from Kreos Capital, a growth debt capital provider for startups.
